SCHEMBL3019030

SCHEMBL3019030

COc1ccc(OC)c(Cc2csc(N3CCC(S(=O)(=O)c4cccc(Cl)c4)CC3)n2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 3/20 0.39
MAOA P21397 2/20 0.39
F2 P00734 1/20 0.38
F2RL3 Q96RI0 1/20 0.38
HTR7 P34969 2/20 0.38
KCNQ1 P51787 1/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TP53 P04637 2/20 0.37
MAPT P10636 5/20 0.37
LMNA P02545 2/20 0.37
RECQL P46063 2/20 0.37
POLB P06746 1/20 0.37
ADRB2 P07550 1/20 0.37
TSHR P16473 1/20 0.37
MEN1 O00255 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KMT2A Q03164 2/20 0.36
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3004005 0.93 F2 (0.40) KDM1AMAOAF2F2RL3HTR7
SCHEMBL3020144 0.93 RAB9A (0.38) RAB9ASMN1; SMN2TP53MAPTLMNA
SCHEMBL3001553 0.92 CMA1 (0.41) KDM1AMAOAKCNQ1RAB9ASMN1; SMN2
SCHEMBL3007560 0.91 KDM1A (0.40) KDM1AF2F2RL3HTR7KCNQ1
SCHEMBL3012854 0.90 THRB (0.41) KCNQ1RAB9ASMN1; SMN2TP53MAPT
SCHEMBL3016957 0.90 TP53 (0.37) RAB9ASMN1; SMN2TP53MAPTLMNA
SCHEMBL2998369 0.89 RAB9A (0.37) RAB9ASMN1; SMN2TP53MAPTLMNA
SCHEMBL3002108 0.89 ALDH1A1 (0.39) RAB9ASMN1; SMN2TP53MAPTLMNA
SCHEMBL3017438 0.89 KDM4E (0.43) F2RL3RAB9ASMN1; SMN2TP53MAPT
SCHEMBL3022378 0.89 MAPT (0.39) RAB9ASMN1; SMN2TP53MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KDM1A 3548/4885MAOA 4561/4885F2 4807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.